AstraZeneca’s Voydeya recommended for approval in EU by CHMP
February 29, 2024Medical Communications AstraZeneca, CHMP, EMA, Haematology, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee …
Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance
February 29, 2024Medical Communications FDA, Infections and infestations, Spero Therapeutics, bacterial infections, investigational new drug
Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug …
Viatris and Idorsia enter research and development collaboration
February 28, 2024Research and Development Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus
Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …
Amneal and Zambon Biotech enter agreement for Parkinson’s treatment
February 28, 2024Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement
Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …
GSK shares positive results from phase 3 trial for gonorrhoea treatment
February 27, 2024Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea
GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …
Amgen opens new biomanufacturing facility in Ohio, US
February 27, 2024Manufacturing and Production Amgen, Biomanufacturing, Manufacturing Facility, Ohio, Pharmacy, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. This will be the latest …
Roche shares data from phase 3 trial of Xolair as allergy treatment
February 26, 2024Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
February 26, 2024Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …
AbbVie and Tentarix collaborate on oncology and immunology treatments
February 23, 2024Research and Development AbbVie, Oncology, collaboration, immunology
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
February 23, 2024Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
February 22, 2024Medical Communications FDA, Oncology, Regeneron, bla, priority review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …
BioAscent opens new protein production facility
February 22, 2024Manufacturing and Production BioAscent, Pharmacy, facility, protein production
BioAscent has announced that it has opened its new state-of-the-art protein production facility in an event chaired by Professor Michael …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
February 21, 2024Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …
Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment
February 21, 2024Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical
Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
February 20, 2024Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …
argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment
February 20, 2024Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA
argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
February 19, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
February 19, 2024Medical Communications Iovance, Oncology, accelerated approval, melanoma
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
February 16, 2024Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
Freenome raises $254m funding for early cancer detection platform
February 16, 2024Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding
Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …
Latest content
FibroFind appoints Lee Borthwick as CEO
